November 2023
Memo TherapeuticsMemo Therapeutics AG Appoints Erik van den Berg as Chief Executive Officer (CEO)
August 2023
Alentis TherapeuticsAlentis Therapeutics receives FDA Fast Track Designation for ALE.C04 for the Treatment of Claudin-1 Positive HNSCC
August 2023
Hummingbird BioscienceHummingbird Bioscience Initiates HMBD-001 Phase IB Trials in Australia and Partners with Omico to Accelerate Clinical Development
June 2023
Alentis TherapeuticsAlentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
June 2023
Ariceum TherapeuticsAriceum Snaps up Fellow European Biotech Theragnostics to Bolster Radiopharma Efforts
June 2023
Ariceum TherapeuticsAriceum Therapeutics Expands Pipeline with Acquisition of Theragnostics Ltd
May 2023
Engimmune TherapeuticsEngimmune Therapeutics Announces the Appointment of Dr Annalisa D’Andrea to its Board of Directors
May 2023
Hummingbird BioscienceHummingbird Bioscience and Merck Enter Collaboration to Evaluate HMBD-001 In Squamous Non-Small Cell Lung Carcinoma
April 2023
Alentis TherapeuticsAlentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-ascending Dose Cohorts Study
April 2023
Engimmune TherapeuticsEngimmune Therapeutics Appoints Dr. Lars Nieba as Chief Executive Officer
April 2023
Alentis TherapeuticsAlentis Therapeutics Closes $105 Million Series C Funding to Advance Transformational Medicines for Claudin-1
March 2023
Mediar TherapeuticsMediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies
March 2023
Pureos BioventuresPureos Partners Welcomes Prof. Dr. Sai Reddy to its Team as Venture Partner
February 2023
Ariceum TherapeuticsAriceum Therapeutics Appoints Radioligand Expert, Germo Gericke, M.D., as Chief Medical Officer
January 2023
Pureos BioventuresPureos Partners Welcomes Dr. Ulf Grawunder to its Team as Venture Partner
January 2023
Alentis TherapeuticsPositive Results from Single Ascending Dose Phase 1 Study of ALE.F02 Targeting Claudin-1
January 2023
Alentis TherapeuticsAlentis Therapeutics Appoints Dr. Luigi Manenti as Chief Medical Officer
January 2023
Hummingbird BioscienceHummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program
December 2022
Hummingbird BioscienceCaris Life Sciences and Hummingbird Bioscience Enter Into Collaboration to Advance Clinical Development of Anti-HER3 Therapy
November 2022
ImCheck TherapeuticsImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting
November 2022
Alentis Therapeutics Alentis Therapeutics Announces Presentations at AASLD The Liver Meeting® 2022
October 2022
Ariceum TherapeuticsAriceum Therapeutics and AmbioPharm Enter Strategic Manufacturing and Supply Partnership
October 2022
Alentis TherapeuticsSwiss Innovation Agency to co-fund Research Collaboration to Accelerate Discovery of Biomarkers for Fibrosis
September 2022
Pureos BioventuresPureos Partners Welcomes Dr. Veronica Gambillara Fonck as New Partner to its Investment Team
September 2022
Hummingbird BioscienceHummingbird Bioscience Announces Trial in Progress Poster Presentation at the European Society for Medical Oncology Congress 2022
May 2022
Alentis TherapeuticsAlentis Therapeutics Appoints Dr. Andrea Pellacani as Chief Medical Officer
May 2022
Engimmune TherapeuticsEngimmune Therapeutics Raises CHF 15.5 Million in Seed Financing to Develop Novel T-Cell Receptor Therapeutics
February 2022
Hummingbird BioscienceHummingbird Bioscience Publishes Preclinical Data Demonstrating Therapeutic Potential of HMBD-002 in VISTA-expressing Cancers
February 2022
ImCheck TherapeuticsImCheck Announces First Patients Dosed in Phase II of EVICTION Trial for ICT01
January 2022
Alentis TherapeuticsAlentis Therapeutics Starts First-in-Human Clinical Trial for the Treatment of Liver and Kidney Fibrosis
December 2021
Acrivon TherapeuticsAcrivon Therapeutics Announces its Scientific Advisory Board with Renowned Oncology Thought Leaders
December 2021
Hummingbird BioscienceHummingbird Bioscience Announces First Patient Dosed in Phase 1 Clinical Trial of HMBD-001 in Advanced HER3-Expressing Solid Malignancies
November 2021
Hummingbird BioscienceHummingbird Bioscience Appoints Jan Møller Mikkelsen as Chairman of the Board
November 2021
Lava TherapeuticsLAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
November 2021
ImCheck TherapeuticsImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at SITC Meeting 2021
November 2021
Araris BiotechAraris is Expanding its Scientific Advisory Board with Dr. Jeff Sharman and Dr. Clive Stanway
November 2021
Hummingbird BioscienceHummingbird Bioscience Announces Trials in Progress Poster Presentation at the Society for Immunotherapy of Cancer 2021 36th Annual Meeting
November 2021
Pureos BioventuresPureos Bioventures Welcomes Dr. Lars Nieba to its Team as Venture Partner
November 2021
Alentis TherapeuticsAlentis Therapeutics Announces Appointments of Luca Santarelli to the Board of Directors and Rafaele Tordjman as Chairperson
October 2021
Hummingbird BioscienceHummingbird Bioscience to Present Pre-Clinical Data on Novel Biomarkers for HER3-Driven Cancers
September 2021
Pureos BioventuresPureos Bioventures Expands the Team by the Appointment of Venture Partners
September 2021
ImCheck TherapeuticsImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021
September 2021
Araris BiotechAraris Biotech Shortlisted in Top 5 of World ADC Awards 2021 in Category “Best ADC Platform Technology“
September 2021
Hummingbird BioscienceHummingbird Bioscience Announces US FDA Clearance of IND for First-in-Human Phase 1 Trial of HMBD-002 in Patients with Advanced Solid Tumors
September 2021
ImCheck TherapeuticsImCheck to Present Early Patient Response Data from the EVICTION Trial at the ESMO Congress 2021
August 2021
Lava TherapeuticsLAVA Therapeutics Provides Business Update and Reports Second Quarter Results
June 2021
Corlieve TherapeuticsuniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)
April 2021
ImCheck TherapeuticsImCheck Announces Initiation of U.S. Enrollment in Phase I/IIa EVICTION Trial for ICT01
More News News Archive